iRhythm Brass Face Suit Over FDA's Heart Monitor Inquiry

By Katryna Perera · May 20, 2024, 6:22 PM EDT

Several current and former directors and executives of medical technology company iRhythm are named in a shareholder derivative suit alleging they failed to disclose an inquiry by the Food and Drug...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Ayers v. iRhythm Technologies, Inc. et al

Case Number

Court

Delaware

Nature of Suit

Securities/Commodities

Date Filed

May 17, 2024

Recent Articles By Katryna

October 28, 2024
SEC Sues To Enforce Subpoena On Telehealth Co.
September 27, 2024
Pharma Co. Amarin Beats Class Action Over Patent Issues
September 26, 2024
Healthcare REIT Defeats Investor Suit For Good
September 23, 2024
Mallinckrodt Brass Can't Avoid Investor Suit Over 2nd Ch. 11
September 23, 2024
SEC Scores $12M Judgment In Unregistered Dealer Case
September 05, 2024
Pharma Co. Verrica Fails To Shed Investor Suit Over FDA OK
August 21, 2024
Health Co. Investors Fight To Keep Suit Over Migrant Deal
August 06, 2024
Pharma Co. Founder Beats Suit Over Short-Swing Trading
August 05, 2024
Indivior Accused Of Overstating Prospects Of 3 Opioid Drugs
August 05, 2024
Centessa Beats Shareholder Suit Over Kidney Drug